This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Literatur
Anagrelide Study Group (1992) Anagrelide, a therapy for thrombocythemic states. Experience in 577 patients. Am J Med 92: 69–76
Chronic Myeloid Leukemia Trialists’ Collaborative Group (1997) Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 89: 1616–1620
Cortelazzo S, Finazzi G, Ruggeri M et al. (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332: 1132–1136
Gratwohl A, Hermans J, Goldman JM et al. (1998) Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 352: 1087–1092
Hasford J, Pfirrmann M, Hehlmann R et al. (1998) A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alpha. J Natl Cancer Inst 90: 850–858
Landolfi R, Marchioli R, Kutti J et al. (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350: 114–124
Lengfelder E, Hochhaus A, Kronawitter U et al. (1998) Should a platelet limit of 600×109/l be used as a diagnostic criterion in essential thrombocythemia? An analysis of the natural course including early stages. Brit J Haematol 100: 15–23
Löfvenberg E, Wahlin A (1988) Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 41: 375–381
O’Brien S, Guilhot F, Larson RA et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994–1004
Sawyers CL, Hochhaus A, Feldman E et al. (2002) Gleevec/GlivecTM (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood 99: 3530–3539
Tefferi A (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med 342: 1255–1265
Literatur
Ades L, Mary JY, Ferry C et al. (2004) Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 103: 2490–2797
Bacigalupo A, Brand R, Oneto R et al. (2000) Treatment of acquired severe aplastica anemia: Bone marrow transplantation compared with immunosuppressive therapy — The European Group for Blood and Marrow Transplantation experience. Semin Hematol 37: 69–80
Frickhofen N, Heimpel H, Kaltwasser JP et al. (2003) Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 101: 1236–1242
Marsh JCW, Ball SE, Darbyshire P et al. (2003) Guidelines for the diagnosis and management of acquired aplastic anemia. Br J Haematol 123: 782–801
Literatur
Hall C, Richards S, Hillmen P (2003) Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 102: 3587–3591
Hillman P, Hall C, Marsh JWC et al. (2004) Effect of Eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. New Engl J Med 350: 552–559
Suenaga K, Kanda Y, Niiya H et al. (2001) Successful application of nonmyeloablative transplantation for paroxysmal nocturnal hemoglobinuria. Exp Hematol 29: 639–642
Literatur
Delannay J, Iolascon A (1999) The congenital dyserythropoietic anemias. Best Pract Res Clin Haematol 12: 691–705
Heimpel H, Anselstetter V, Chrobak L et al. (2003) Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis based on long-term observation. Blood 102: 4576–4581
Iolascon A, Sabato V, de Mattia D, Loctalli F (2001) Bone marrow transplantation in a case of severe, type II congenital dyserythropoetic anemia (CD II). Bone Marrow Transplant 27: 213–215
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag Heidelberg
About this chapter
Cite this chapter
Hehlmann, R. et al. (2005). Stammzellerkrankungen. In: Schölmerich, J., et al. Medizinische Therapie 2005|2006. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27385-9_27
Download citation
DOI: https://doi.org/10.1007/3-540-27385-9_27
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-21226-3
Online ISBN: 978-3-540-27385-1
eBook Packages: Medicine (German Language)